VIVUS — Investor Presentation (April 2013)
27 slides from VIVUS's investor presentation, Apr 30, 2013
Slide 1: Innovative Therapies Novel Products
INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains “forward looking” statements that involve risks and uncertainties. These statements typically may be identified by the use of forward looking words or phrases such as “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “shou
Slide 3: Innovative Therapies; Novel Products
INNOVATIVE THERAPIES; NOVEL PRODUCTS Two approved products in high potential markets: Qsymia™ for chronic weight management STENDRA™ for erectile dysfunction ©2013 VIVUS Inc. All rights reserved | www.vivus.com 2
Slide 4: Qsymia Prescribing Information
QSYMIA PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 3 About Qsymia Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese)
Slide 5: Qsymia Efficacy
QSYMIA EFFICACY Magnitude Double-digit weight loss Consistency 84% of patients achieve ≥3% weight loss after 12 weeks (Mid Dose) 90% of patients achieve ≥5% weight loss after 28 weeks (Top Dose) Multiple Benefits Positive impact on cardiometabolic parameters ©2013 VIVUS Inc. All rights reserved | ww
Slide 6: Qsymia Magnitude of Effect
QSYMIA MAGNITUDE OF EFFECT PIVOTAL 1-YEAR STUDIES: WEIGHT LOSS OVER TIME (OBSERVED DATA) ©2013 VIVUS Inc. All rights reserved | www.vivus.com 5 Study 1 (EQUIP) Study 2 (CONQUER) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or Low T
Slide 7: Beneficial Effects of Weight Loss with Qsymia
BENEFICIAL EFFECTS OF WEIGHT LOSS WITH QSYMIA ©2013 VIVUS Inc. All rights reserved | www.vivus.com 6 Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted
Slide 8: Qsymia: Recent Successes
QSYMIA: RECENT SUCCESSES Increase in prescription growth Approval of REMS modification to allow access via certified retail pharmacies Medco coverage of Qsymia New AACE Guidelines include anti-obesity medications Publication of pharmacoeconomic data ©2013 VIVUS Inc. All rights reserved | www.vivus.c
Slide 9: Steady Growth in Qsymia Prescriptions
Source: VIVUS, Inc. Data on file – 31-Mar-2013 Q-o-Q Growth % 97% STEADY GROWTH IN QSYMIA PRESCRIPTIONS 8 TRxs 70 60 50 40 30 20 10 0 (000s) 29.9 59.0 4Q2012 1Q2013
Slide 10: Steady Growth in Qsymia Prescriptions
M-o-M Growth % 10% 29% Source: VIVUS, Inc. Data on file – 31-Mar-2013 STEADY GROWTH IN QSYMIA PRESCRIPTIONS 9 TRxs 30 25 20 15 10 5 0 Jan-2013 Feb-2013 Mar-2013 16.7 18.4 23.8 (000s)
Slide 11: REMS Modification Approved
REMS MODIFICATION APPROVED Removes a significant barrier to Qsymia commercialization Simplifies prescribing and dispensing Availability in certified retail pharmacies expected 3Q 2013 ©2013 VIVUS Inc. All rights reserved | www.vivus.com 10
Slide 12: Retail Implementation Plan
RETAIL IMPLEMENTATION PLAN 90-Day Plan Execute wholesaler distribution agreements Build distribution network Build and validate REMS-compliant databases Enroll, train and certify pharmacies (chain/independent) Ship to distribution centers Stock certified pharmacies ©2013 VIVUS Inc. All rights reserv
Slide 13: Qsymia Covered on Medco Plans
QSYMIA COVERED ON MEDCO PLANS Qsymia now covered for plans following the Medco national formulary ESI/Medco: largest U.S. Pharmacy Benefit Manager (PBM) Manages pharmacy benefit for 64.3MM U.S. lives* Tier 3; Prior Authorization Co-pay: ~$50 - $60, depending on benefit design ©2013 VIVUS Inc. All ri
Slide 14: AACE Treatment Guidelines Include Anti-Obesity Medications
AACE TREATMENT GUIDELINES INCLUDE ANTI-OBESITY MEDICATIONS ©2013 VIVUS Inc. All rights reserved | www.vivus.com 13 Qsymia included in guidelines
Slide 15: AACE Treatment Guidelines Include Anti-Obesity Medications
AACE TREATMENT GUIDELINES INCLUDE ANTI-OBESITY MEDICATIONS ©2013 VIVUS Inc. All rights reserved | www.vivus.com 14
Slide 16: AACE Treatment Guidelines Include Anti-Obesity Medications
AACE TREATMENT GUIDELINES INCLUDE ANTI-OBESITY MEDICATIONS ©2013 VIVUS Inc. All rights reserved | www.vivus.com 15
Slide 17: AACE Treatment Guidelines Include Anti-Obesity Medications
AACE TREATMENT GUIDELINES INCLUDE ANTI-OBESITY MEDICATIONS ©2013 VIVUS Inc. All rights reserved | www.vivus.com 16
Slide 18: AACE Treatment Guidelines Include Anti-Obesity Medications
AACE TREATMENT GUIDELINES INCLUDE ANTI-OBESITY MEDICATIONS Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension First-ever inclusion of drug therapy in guidelines Primary Care Physicians refer to AACE guidelines ©2013 VIVUS
Slide 19: Publication of Pharmacoeconomic Data Helps Reimbursement
PUBLICATION OF PHARMACOECONOMIC DATA HELPS REIMBURSEMENT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 18 10%-15% weight loss = gross per capita savings of ~$6,000-$13,000 over 10 years With ~11.2 million Medicare patients who are obese or overweight with at least one weight-related comorbidi
Slide 20: Building the Qsymia Franchise
Educate Physicians Broaden Reimbursement Expand to Retail Pharmacies DTC & Expand PCP Reach BUILDING THE QSYMIA FRANCHISE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 19 Launch Time Rx Growth
Slide 21: STENDRA: Partnering for Value
STENDRA: PARTNERING FOR VALUE ©2013 VIVUS Inc. All rights reserved | www.vivus.com
Slide 22: STENDRA Prescribing Information
STENDRA™ PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 21 About STENDRA™ STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to
Slide 23: STENDRA
Highly selective PDE5i with rapid onset Positive CHMP recommendation (26-Apr-2013) Opportunity to commercialize in the US and EU* *Pending EMA approval Manufacturing technology transfer underway Partnering discussions in progress ©2013 VIVUS Inc. All rights reserved | www.vivus.com 22 STENDRA™
Slide 24: Royalty Financing (26-Mar-2013)
ROYALTY FINANCING (26-MAR-2013) $110 million synthetic capped royalty financing $50 MM drawn, $60 MM available to draw by YE2013 Facility provides capital and flexibility to expand Not equity linked No payments for first year Quarterly payment variable depending on Qsymia sales ©2013 VIVUS Inc. All
Slide 25: VIVUS Investment Highlights
VIVUS INVESTMENT HIGHLIGHTS Two FDA-approved products Making significant progress in building the obesity category and Qsymia brand Educating physicians Expanding reimbursement Improving access (REMS modification) Growing Qsymia prescriptions Strong Balance Sheet Cash, equivalents & securities [YE20
Slide 26: Important Additional Information
IMPORTANT ADDITIONAL INFORMATION VIVUS, its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from VIVUS stockholders in connection with the matters to be considered at VIVUS’s 2013 Annual Meeting of Stockholders. VIVUS intends to file a
Slide 27: Innovative Therapies Novel Products
INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com